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The voltage-dependent ClC-1 chloride channel belongs to the CLC channel/transporter
family. It is a homodimer comprising two individual pores which can operate
independently or simultaneously according to two gating modes, the fast and the slow
gate of the channel. ClC-1 is preferentially expressed in the skeletal muscle fibers
where the presence of an efficient Cl− homeostasis is crucial for the correct membrane
repolarization and propagation of action potential. As a consequence, mutations in
the CLCN1 gene cause dominant and recessive forms of myotonia congenita (MC),
a rare skeletal muscle channelopathy caused by abnormal membrane excitation, and
clinically characterized by muscle stiffness and various degrees of transitory weakness.
Elucidation of the mechanistic link between the genetic defects and the disease
pathogenesis is still incomplete and, at this time, there is no specific treatment for
MC. Still controversial is the subcellular localization pattern of ClC-1 channels in skeletal
muscle as well as its modulation by some intracellular factors. The expression of ClC-1
in other tissues such as in brain and heart and the possible assembly of ClC-1/ClC-2
heterodimers further expand the physiological properties of ClC-1 and its involvement
in diseases. A recent de novo CLCN1 truncation mutation in a patient with generalized
epilepsy indeed postulates an unexpected role of this channel in the control of neuronal
network excitability. This review summarizes the most relevant and state-of-the-art
research on ClC-1 chloride channels physiology and associated diseases.
Keywords: ClC-1 chloride channel, skeletal muscle physiology, myotonia congenita, ion channel pharmacology,
skeletal muscle plasticity
Introduction
CLCproteins are ubiquitous chloride channels/transporters playing important roles in many phys-
iological and physiopathological processes (Hille, 1992). Their story began with the electric ﬁsh,
which expresses a high number of voltage-gated chloride channels in the cell of an electric organ
originated from the skeletal muscle tissue (White and Miller, 1979). Due to the lack of speciﬁc
inhibitors and the diﬃculties of biochemical puriﬁcation, it was only in the 1990s that a molecu-
lar identiﬁcation of voltage-gated chloride channels was made. In these years, the chloride channel
from Torpedo marmorata, called ClC-0, was cloned with an elegant but extremely sophisticated
expression cloning strategy (Jentsch et al., 1990). This allowed the description of a large family
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of CLC proteins homologous to ClC-0 and expressed in organ-
isms within the kingdoms of life from eubacteria to animals
(Jentsch et al., 1999; Maduke et al., 2000). These proteins exhibit a
high degree of evolutionary conservation and function as homod-
imers (Middleton et al., 1996). In mammalian tissues, nine diﬀer-
ent CLC proteins have been identiﬁed, divided into plasma mem-
brane Cl− channels and vesicular Cl−/H+-exchangers (Jentsch,
2015).
The ClC-1 channel was the ﬁrst member of the CLC family
cloned in mammals (Steinmeyer et al., 1991a). In humans, the
CLCN1 gene is located on chromosome 7q35 and codes for a
protein of ∼990 amino acids in length. This channel is mainly
expressed in the skeletal muscle, where it supports the large
chloride conductance of sarcolemma. Its physiological role was
discovered by analyzing a mouse model of myotonia congenita
(MC), a genetic disease of the skeletal muscle characterized by a
reduced sarcolemma chloride conductance. A plethora of muta-
tions in the CLCN1 gene are known to produce dominant and
recessive myotonia in humans and other animals. At lower levels
it has been detected in kidney, heart, smooth muscle, and, more
recently, in the central nervous system (Steinmeyer et al., 1991a;
Chen et al., 2013). This review describes our current knowledge
regarding ClC-1 channels, as a example for using human genetic
diseases and mouse models to facilitate the elucidation of the
cellular roles of ion channels, and the research challenges these
proteins continue to oﬀer twenty-ﬁve years after the cloning of
the ﬁrst CLC.
Molecular Structure and Function of
ClC-1
The ClC-1 voltage-gated chloride channel belongs to the CLC
family, which comprises nine members in humans, named ClC-
1 through ClC-7, plus ClC-Ka and ClC-Kb. They were initially
assumed to behave as chloride ion channels, but successive exper-
iments revealed that ﬁve out of the nine hClCs (ClC-3 through
ClC-7) rather function as anion-proton exchangers (Picollo and
Pusch, 2005; Scheel et al., 2005; Neagoe et al., 2010; Leisle et al.,
2011; Guzman et al., 2013). Experimental data also support a
close structural similarity among the members of the CLC family.
Actually, most of the current information about the 3D structure
of ClC-1 channels have been derived from the analysis of CLC
anion-proton exchangers crystallized from several prokaryotic
(EcCLC) and eukaryotic species (CmCLC; Figure 1A; Dutzler
et al., 2002; Accardi et al., 2006; Lobet and Dutzler, 2006; Feng
et al., 2010; Robertson et al., 2010; Jayaram et al., 2011; Lim
et al., 2012). The ClC-1 channel is a dimer of two homologous
subunits, each forming a chloride ion conducting pore indepen-
dent from the other, allowing ClC-1 to function as a “double-
barrel” channel (Saviane et al., 1999). Each subunit consists of 18
domains (helices A-R) and two tandem cystathionine-β-synthase
(CBS) domains located in the intracellular C-terminal (Meyer
and Dutzler, 2006; Markovic and Dutzler, 2007). According to
the 3D structures, membrane helices D, F, N, and R contribute to
the ClC ion transport pathway, helices H, I, P, and Q form part
of the interface between the two monomers, and helix R connects
the transmembrane segments of the channel to the C-terminal
domain (Dutzler et al., 2002, 2003; Feng et al., 2010). Each pore
contains three separate chloride ion binding sites, named Sint,
Scen, and Sext according to their position relative to the extra-
or intracellular side of the plasma membrane. The Scen position
forms a signiﬁcant part of the selectivity ﬁlter where conserved
and less well conserved aminoacids coordinate the chloride ion
within the conduction pathway (Dutzler et al., 2002, 2003; Lobet
and Dutzler, 2006).
Early single channel recordings of ClC-1 channels expressed
in heterologous systems, demonstrate two conductance states
and conﬁrmed the existence of two ion conduction pathways for
homodimeric ClC channel, as shown for ClC-0 (Miller, 1982;
Miller and White, 1984; Pusch et al., 1994; Saviane et al., 1999).
Whole cell recordings of hClC-1 channels in high chloride intra-
cellular solution show chloride currents that rapidly activate and
deactivate at negative potentials and that saturate at positive
potentials (Figure 1B).
Channel opening in ClC-1 is regulated by two distinct gating
patterns: fast (or single-pore) and slow (or common-pore) gating
(Accardi and Pusch, 2000; Dutzler, 2006), fast gating being about
10-fold faster than common gating (Miller, 1982; Saviane et al.,
1999; Stölting et al., 2014b). The slow gate controls the opening
and closing of the two subunits simultaneously, whereas the fast
gate regulates the function of independent pores (Saviane et al.,
1999). The carboxyl side chain of glutamate residue E232 of helix
F is the main responsible for the fast gating: it projects into the
extracellular-facing portion of the ion conduction pathway and
functions as the voltage-, Cl−- and H+-activated fast gate, dis-
closing Sext when protonated (Zifarelli and Pusch, 2007). This
residue is part of the Gly-Lys/Arg-Glu-Gly-Pro sequence motif
that is conserved in all CLC channels apart from the kidney chan-
nels ClC-Ka and CIC-Kb. The molecular identity of the slow gate
has still to be elucidated, and how the slow gate closes simulta-
neously both pores is still unknown. Far from simply involving
helices and residues at the dimer interface, the emerging view
on the mechanism of cooperative gating predicts the occurrence
of concerted conformational changes involving the residue E232
in the channel pore, the intra-membrane interface between two
monomers, and the C-terminal CBS domains via helix R (Duﬃeld
et al., 2003; Estévez et al., 2004; Fialho et al., 2007; Cederholm
et al., 2010; Feng et al., 2010; Ma et al., 2011; Bennetts and Parker,
2013). Recently, it has been proposed that the slow channel clo-
sure depends on the H-bond formation between the E232 of pore
helix F and the Y578 of the linker helix R (Bennetts and Parker,
2013). This H-bond interaction would enable the occlusion of
the central anion binding site of the channel, thus hindering Cl−
ﬂow.
The intracellular C-terminal of ClC-1 is a poorly char-
acterized region. This portion, comprising two tandem CBS
domains, is common to the eukaryotic CLC members, and
appears to be relevant for ClC-1 expression, slow gating and
intracellular modulation (Figure 1A; Meyer and Dutzler, 2006;
Markovic and Dutzler, 2007; Tseng et al., 2007; Zhang et al.,
2008; Hsiao et al., 2010; Bennetts et al., 2012; Bennetts and
Parker, 2013). The crystal structure of the eukaryotic CLC
protein demonstrates that CBS2 lies functionally close to the
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FIGURE 1 | Structure, function, and modulation of hClC-1 channels.
(A) Upper panel, diagram showing residues relevant for ClC-1 channel
gating, E232 (green) and Y578 (magenta), and putative binding sites for
Zn2+ (C277, blue), 9-AC (S537, violet), ATP (V613, V634, V860, E865,
yellow), NAD+ (T636, H847, L848, red), PKC (Thr891, Ser892, Thr893,
gray). Lower panel, three dimensional front view of hClC-1 channel
modeled upon the structure of CmClC, including relevant residues for
channel function and regulation. (B) Representative chloride currents
recorded from tsA cells transfected with cDNAs coding for hClC-1 WT (up)
and for a MC mutant hClC-1 G190S (down), in the whole-cell configuration
of patch clamp. Note that G190S shows a strong outward rectification
differently from WT. Cells were held at 0 mV and 400 ms voltage pulses
were applied from −180 to +180 mV in 10-mV intervals every 3 s, in high
chloride intracellular solution.
intramembrane domains while CBS1 faces into the cytoplasm
(Feng et al., 2010). CBS2 interacts extensively with the R-
helix linker and helix D, and with an intracellular loop linking
helices H and I. By virtue of its direct connection to the C-
terminus, the R helix could provide a pathway by which intra-
cellular domain conformational changes regulate CLC activity
during cell signaling events or modulate slow gating (Dutzler
et al., 2002; Bykova et al., 2006; Garcia-Olivares et al., 2008;
Feng et al., 2010; Ma et al., 2011; Stölting et al., 2014b).
The presumed regulatory role of the CBS linker, with its
highly variable and largely unstructured sequence, has not been
assessed jet.
To date, no report exists showing that ClC-1 can form het-
eromers with members of the same family in vivo. However, as
ClC-2 is ubiquitously expressed, the spontaneous formation of
heterodimeric ClC-1-ClC-2 channels would be not surprising in
native human tissues, where both channels co-exist under phys-
iological conditions. ClC-1 and ClC-2 chloride channels diﬀer
profoundly in the voltage dependence of fast and slow gating.
Whereas fast and slow opening of ClC-1 is stimulated by mem-
brane depolarization (Stölting et al., 2014a), fast and cooperative
gates of ClC-2 are closed at depolarized potentials and open upon
membrane hyperpolarization (Stölting et al., 2014a). Therefore,
an attempt to clarify the mechanism of cooperative interaction
between subunits has been the functional characterization of
“artiﬁcial” heterodimeric ClC-1-ClC-2 channels consisting of two
functionally distinct ClC pores (Lorenz et al., 1996; Stölting et al.,
2014a). The observation that ClC-1-ClC-2 heterodimeric chan-
nels lack cooperative gating (Stölting et al., 2014a) supports the
idea that slow gating of CLC channels ultimately arises from con-
formational changes within an individual pore (Cederholm et al.,
2010; Bennetts and Parker, 2013; Stölting et al., 2014b). Therefore,
fast and slow gating are now supposed to be closely coupled and
not independent processes, as previously thought.
Modulatory Pathways
The structural bases of ClC-1 gating have been extensively studied
as well as the contribution of ClC-1 channels to skeletal muscle
physiology. How ClC-1 proteins are modulated by cell signaling
pathways is, however, less well understood. There are compelling
evidence that ClC-1 channel is ﬁnely regulated by the metabolic
state of skeletal muscle ﬁbers under physiological conditions, and
its physiological contribution to skeletal muscle excitability must
be read in the context of intracellular adenosine triphosphate
(ATP) content, changes of the cytosolic redox state, alteration of
the β-nicotinamide adenine dinucleotide (NAD+/NADH) ratio,
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membrane depolarization, acidiﬁcation in exercised muscle, and
protein kinases modulation.
The direct eﬀect of cytoplasmic ATP on ClC-1 channels has
been studied by several laboratories with apparently controver-
sial results (Bennetts et al., 2007; Tseng et al., 2007; Zifarelli and
Pusch, 2008). Indeed, Tseng et al. (2007) and Bennetts et al.
(2007) provided evidence that ATP directly inhibits recombi-
nant ClC-1 channels by shifting the voltage dependence of slow
gating to positive potentials, an eﬀect that is enhanced by low
intracellular pH (pHi). This experimental ﬁnding provided a rea-
sonable explanation for previously published eﬀects of pHi on
chloride currents in diﬀerent biological systems (Saviane et al.,
1999; Pedersen et al., 2004, 2005). Indeed, reducing pHi was
shown to slow deactivation and increase the open probability of
heterologously expressed ClC-1 channels (Rychkov et al., 1996;
Saviane et al., 1999; Accardi and Pusch, 2000). Conversely, the
acidiﬁcation of skeletal muscle cells was reported to decrease sar-
colemmal chloride conductance, thus maintaining the essential
excitability in the partially depolarized sarcolemma and limit-
ing muscle fatigue (Pedersen et al., 2004, 2005). ATP binding to
the intracellular side of ClC-1 C-terminus could be the prerequi-
site required to observe a reduction of the ClC-1 conductance at
low pHi in intact muscle ﬁbers, thus reconciling these apparently
divergent results (Bennetts et al., 2007; Tseng et al., 2007). Despite
these exhaustive experiments, Zifarelli and Push questioned the
direct pHi-dependent ATPmodulation of ClC-1, as they failed to
detect any ATP block in inside-out patches from Xenopus oocytes
expressing ClC-1 channels (Zifarelli and Pusch, 2008). The hid-
den culprit underlying this further controversy seems to rely on
the oxidation of ClC-1. Indeed, it seems that the ATP-mediated
inhibition of ClC-1 channels is dependent on the redox-state of
the cell, disappearing in the oxidizing condition of excised inside-
out patches whereas being evident when adding reducing agents
to the patch (Zhang et al., 2008). Oxidation of ClC-1 might thus
be one of the mechanisms that control the muscle response to
fatigue, by regulating the ATP inhibition of ClC-1 (Zhang et al.,
2008). As ATP, also NAD+ has been shown to aﬀect the slow
channel gating in a pHi-dependent mode by binding to the CBS
domains of ClC-1 (Bennetts et al., 2012). Through mutagenesis
experiments, relevant residues within both CBS domains form-
ing a putative binding site for both ATP and NAD+ have been
highlighted (Figure 1A; Bennetts et al., 2007; Tseng et al., 2007).
Zn2+ ions are also known to block ClC-1 channels by facilitat-
ing closing of the slow gate of ClC-1 (Duﬃeld et al., 2005). This
eﬀect is eliminated by themutation C277Swhich greatly increases
the minimal open probability of the slow gate in ClC-1 channels,
and is facilitated by the mutant V321A, which reduces the open
probability of slow gating (Accardi et al., 2001; Duﬃeld et al.,
2005).
Several pharmacological and molecular studies indicate
that ClC-1 is regulated by protein phosphorylation events
(Brinkmeier and Jockusch, 1987; Bryant and Conte-Camerino,
1991; Tricarico et al., 1991; Rosenbohm et al., 1999; Papponen
et al., 2005; Camerino et al., 2014). The external application
of 4β-phorbol esters on HEK 293 cells transfected with hClC-1
channels reduced the instantaneous whole-cell current amplitude
(Rosenbohm et al., 1999). This eﬀect was abolished when the
cells were intracellularly perfused with a speciﬁc protein kinase
C (PKC) inhibitor, chelerythrine, suggesting that the eﬀect of
4β-phorbol esters was mediated by PKC. The C-terminal region
seems at least in part responsible for the eﬀect of PKC acti-
vation on ClC-1 channels: indeed, several serine residues have
been identiﬁed in the C-terminal domain which mediate PKC-
dependent inhibition of ClC-1 chloride currents (Figure 1A;
Hsiao et al., 2010). Consistently, the chloride conductance of
sarcolemma at rest (gCl), which is mainly supported by ClC-
1, was shown to be reduced by activation of PKC or increased
by inhibitors of PKC. Such an eﬀect may have important
implications for skeletal muscle function (Bryant and Conte-
Camerino, 1991; De Luca et al., 1998; Pierno et al., 2007;
Pedersen et al., 2009b; Camerino et al., 2014). Phosphorylation–
dephosphorylation signaling was shown to be relevant also for the
correct targeting of ClC-1 to sarcolemma in skeletal muscle ﬁbers
(Papponen et al., 2005). Furthermore, electrophysiological stud-
ies showed an increase of gCl in the PKCθ-null mice with respect
to wild-type, and a consequent reduction of muscle excitability
(Camerino et al., 2014). Regulation of ClC-1 channels through
PKC-dependent phosphorylation appeared to be involved in
the muscular eﬀects of a number of growth factors, hormones,
and drugs, including the growth hormone, insulin-like growth
factor-1 (IGF-1), ghrelin, angiotensin II, growth hormone secre-
tagogues, and statins (De Luca et al., 1994b, 1998; Pierno et al.,
2003; Cozzoli et al., 2014).
The hypothesis that accessory subunits may exist and bind to
the C-terminal region, as shown for other channels, cannot be
excluded as well as the possible interaction of the carboxyl tail
of ClC-1 with cytoskeletal elements in muscle cells. Such interac-
tions may be necessary for the integrity of the cytoskeleton as well
as for the homeostatic control of sarcolemmal ClC-1 content or
function.
Physiological Roles of ClC-1
Muscle Excitability
The exact localization of ClC-1 channels in the skeletal mus-
cle membrane is still debated (Lueck et al., 2010; Lamb et al.,
2011). Studies performed on skinned muscle ﬁbers provided evi-
dence that the majority of the chloride conductance is located in
the T-system (Dutka et al., 2008). This result is not surprising if
one considers that a large Cl− conductance would be expected
to dampen membrane depolarization due to K+ accumulation
in the narrow T-tubular space during repetitive muscle stimu-
lation. However another study, by recording chloride currents
in the same dissociated mouse ﬂexor digitorum brevis (FDB)
muscle ﬁbers before and after disconnection of the T-tubules by
osmotic shock, argued for an exclusive expression in the sur-
face membrane (Lueck et al., 2010). A particularly strong point
of this latter study is that the authors did not see any signiﬁ-
cant reduction of ClC-1 currents after detubulation. In this case,
the distantly localized sarcolemmal gCl would exert a “remote
control” on the T-system guaranteeing an eﬃcient control of
the tubular membrane potential (Lueck et al., 2010; Zifarelli and
Pusch, 2010). Several arguments supported this view. First, an
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exclusive sarcolemmal localization of ClC-1 would maintain a
very negative chloride equilibrium potential allowing a higher
buﬀering capacity. Second, in the absence of a large gCl in the
T-tubules, the resting conductance of the T-tubular membrane
would be small, allowing faster and less energy consuming action
potential propagation. The more recent study performed using a
potentiometric dye to measure the T-tubular potential in a region
of a dissociated mouse FDB muscle ﬁber under two-electrode
voltage-clamp, presents evidence for a homogeneous distribu-
tion across T-tubules and the outer sarcolemmal membrane
(DiFranco et al., 2011). Regardless of their exact localization,
ClC-1 channels constitute the main support of the shunting chlo-
ride conductance in the skeletal muscle, allowing the ﬁbers to
electrically tolerate T-tubular membrane invaginations and the
extracellular K+ accumulation subsequent to membrane depolar-
ization.
The study of myotonia pathomechanisms in muscle ﬁbers
from genetically myotonic goats has paved the way for the under-
standing of the physiological role of ClC-1 channels (Bryant,
1969; Bryant and Morales-Aguilera, 1971; Adrian and Bryant,
1974). Diﬀerently from other excitable tissues, the sarcolemma
of adult skeletal muscle ﬁbers at rest presents a characteristic
high chloride conductance (gCl) that is more than fourfold the
potassium conductance (Hodgkin and Horowicz, 1959; Bretag,
1987). Such a large inhibitory Cl− conductance provides the
appropriate balance to the excitatory Na+ currents to guaran-
tee a constant voltage in any particular region of the ﬁber. When
an action potential is triggered, it is propagated along the sur-
face sarcolemma and deep into the interior of ﬁbers via the
T-tubule system. Membrane repolarization initiates after sodium
channel fast inactivation and is completed by potassium eﬄux
through delayed rectiﬁer potassium channels. In normal skele-
tal muscle, potassium accumulation in the T-system causes a
small, transient after-depolarization at the end of muscle con-
traction, but the high resting chloride conductance prevents
propagation of this depolarization along the sarcolemma (Dutka
et al., 2008). Conversely, in myotonic muscle ﬁbers, where the
gCl is dramatically reduced by more than 50%, this potassium
accumulation can trigger autonomous muscle ﬁber action poten-
tials, that result in a prolonged electrical activity even after the
end of neuronal input (the so-called myotonic after-discharges).
This represents the electrophysiological basis for muscle stiﬀ-
ness (Figure 2; Adrian and Bryant, 1974; Steinmeyer et al.,
1991b).
Recently, a series of elegant studies suggested that during a
train of action potentials, the gCl is decreased at the onset of
stimulation mainly due to PKC activation, allowing the work-
ing muscle to maintain neuromuscular transmission and T-
system excitability (Pedersen et al., 2009a,b; Fraser et al., 2011).
Nevertheless, after a determined number of action potentials dur-
ing sustained activity, the gCl is largely increased together with
the potassium conductance supported by ATP-sensitive K+ chan-
nels, most probably in order to terminate muscle activity and
prevent metabolic stress that otherwise would damage the mus-
cle ﬁber (Pedersen et al., 2009a). Interestingly, the rising phase
of sarcolemma conductance during the action potentials train
was not observed in the slow-twitch soleus muscle ﬁbers, which
FIGURE 2 | An animal model of myotonia congenita. (A) Picture of a
homozygous adr/adr mouse carrying a loss-of-function mutation in the clcn1
gene, and showing stiffness in the hindlimb. (B) Typical electromyographic
activity recorded in vivo with needle electrode in the hindlimb musculature of
adr/adr mouse. (C) Typical electrophysiological recordings of excitability
characteristics of adr/adr mouse intercostal muscle fibers with
two-microelectrodes current-clamp technique. Left trace shows a single
action potential elicited by a threshold current. Note the very long latency
between the beginning of current stimulus and action potential onset, due to
the reduced sarcolemmal chloride conductance. The middle trace shows the
typical myotonic after-discharges, when the fiber fires action potentials after
the end of current stimulus. The right trace shows typical myotonic
spontaneous activity in absence of stimulus.
is consistent with the elevated metabolic capacity of slow-twitch
ﬁbers that are rather involved in prolonged contractile activity
(Pedersen et al., 2009b). The molecular mechanism responsible
for the increased gCl is not well deﬁned. It is likely that the con-
sumption of ATP during prolonged activity may contribute to
such an eﬀect, as suggested also by the acceleration of this eﬀect
in glucose-free conditions (Pedersen et al., 2009b). The reduction
of ATP might increase the gCl by completely removing the ATP-
and/or phosphorylation-dependent inhibition of ClC-1 channels.
Altogether these data suggest a pivotal role for ClC-1 channels
for the modulation of muscular fatigue. Accordingly, the depres-
sion of muscle excitability provoked by intense exercise can be
antagonized by inhibition of ClC-1 channels through intracellu-
lar acidiﬁcation, addition of lactate, direct pharmacological block
by 9-anthracen carboxylic acid (9-AC), or by removal of exter-
nal Cl− (Nielsen et al., 2001; Pedersen et al., 2004, 2005; de Paoli
et al., 2010). The more recent study conﬁrms a biphasic relation-
ship between the gCl and contractile endurance in isolated rat
muscles (de Paoli et al., 2013). On one side, the reduction of gCl
increases muscle excitability but, on the other side, reduces the
capacity to maintain K+ homeostasis and membrane potential
during contractions.
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Muscle Plasticity
The ClC-1 channels contribute to determine skeletal muscle phe-
notype and to muscle plasticity. At birth, the sarcolemma gCl
is very low, while it increases during the ﬁrst weeks of post-
natal development under the control of nerve input (Conte
Camerino et al., 1989). The change in gCl is linearly correlated
with changes in ClC-1 channel expression (Steinmeyer et al.,
1991a). In adults, the resting gCl is about 10-fold greater than
the gK in the fast-twitch muscles, while the slow-twitch mus-
cle phenotype is characterized by a ∼50% lower gCl (Bretag,
1987). This diﬀerence is due to a reduced ClC-1 channel expres-
sion and an increased basal PKC-dependent phosphorylation of
the channel in the slow-twitch muscle (Pierno et al., 2007). As
anticipated above, such a phenotypic diﬀerence is of critical rel-
evance for the speciﬁc modulation of ﬁber excitability and the
consequent contractile function. Several evidences also indicate
that the gCl contributes to the determination of muscle phe-
notype. Indeed, the pharmacological block of ClC-1 channels
during the postnatal development forces the fast-twitch mus-
cle to acquire a slow phenotype (De Luca et al., 1990a). Also
in adult animals, the block of ClC-1 channels either through
natural mutations or pharmacological block favors the transi-
tion of fast-twitch muscles toward a less fast phenotype (Salviati
et al., 1986; Goblet and Whalen, 1995). Conversely, during the
unloading condition, such as that encountered in micrograv-
ity condition or in the hindlimb-unloaded rodent model, the
slow-to-fast phenotype shift of the postural slow-twitch soleus
muscle is preceded by an increase of the gCl (Pierno et al.,
2002). Such an increase stems from a reduced activity of the
PKC likely due to changes in nerve input (Pierno et al., 2007).
This indicates that the increase of gCl constitutes an early
event during the adaptation of postural muscle to unloading,
which may be necessary to complete the phenotype transi-
tion.
Aging
In the advanced age (>24 months for rats), the gCl can be dra-
matically reduced in the fast-twitch muscles (De Luca et al.,
1990b, 1994a; De Luca and Conte Camerino, 1992). This reduc-
tion is attributable to a decrease of ClC-1 channel expression
and an increased PKC-dependent phosphorylation of expressed
ClC-1 channels (De Luca et al., 1997a; Pierno et al., 1999). The
later eﬀect may be related to the aging-related increase of calcium
concentration in the muscle ﬁber (Fraysse et al., 2006). Chronic
treatment of aged rats with the growth hormone was able to
restore the gCl in fast-twitch muscles, likely through the induc-
tion of IGF-1 (De Luca et al., 1994b). In turn, IGF-1 was shown
to increase the gCl in aged muscles, at least partially through
the activation of an okadaic acid-dependent phosphatase able to
de-phosphorylate the channel (De Luca et al., 1997a). All the
eﬀects of aging and GH were remarkably ﬁber type dependent,
being less pronounced in the slow-twitch soleus muscle (Fraysse
et al., 2006). Interestingly, chronic treatments of aged rats with
the amino acid taurine or an olive oil-derived mixture, both with
known antioxidant activity, were able to partially counteract the
age-related decline of gCl, suggesting that the oxidative challenge
during the aging process may be involved in the reduction of the
gCl (Pierno et al., 1998, 2014). Based on the role of gCl in the
adult fast-twitch muscle, a reduction of gCl in the aged muscle
would be expected to increase excitability and force endurance.
Nevertheless, the alteration of the entire electrical machinery of
sarcolemma, including sodium, potassium, and calcium chan-
nels, actually impairs excitability and E-C coupling in the aged
muscle (De Luca et al., 1990b, 1992; Tricarico and Camerino,
1994; Delbono et al., 1995; Renganathan et al., 1997; Desaphy
et al., 1998).
Genetic Diseases Associated to ClC-1
Myotonia Congenita
Mutations in the CLCN1 gene, leading to partial or complete
loss of ClC-1 channel function, are responsible for the patho-
genesis of MC (Koch et al., 1992; George et al., 1993; Burge
and Hanna, 2012). This is the most common skeletal muscle
hereditary channelopathy in humans, characterized by mus-
cle stiﬀness after a voluntary movement, that is worse after
rest, and improves with repeated activity according to the so-
called warm-up phenomenon. Inheritance can be dominant
(Thomsen’s disease) or recessive (Becker’s disease), with a more
severe phenotype in the latter form (Colding-Jørgensen, 2005;
Fialho et al., 2007; Raja Rayan and Hanna, 2010). Patients
with recessive MC may also have transient weakness at the
onset of voluntary contraction, that may lead to falls. Diﬀerent
degrees of myotonic symptoms can be reported among family
members with identical ClC-1 mutations and among diﬀerent
families (Colding-Jørgensen, 2005). Chloride channel myoto-
nia also occurs in animals, including goat, mouse, dog, cat,
poney, and water buﬀalo (Figure 2; Steinmeyer et al., 1991b;
Rhodes et al., 1999; Wijnberg et al., 2012; Borges et al., 2013;
Gandolﬁ et al., 2014). The study of myotonia in goats and mice
proved to be decisive to the understanding of the pathomecha-
nism, and eventually allowed the cloning of ClC-1 channel. The
electrophysiological correlate of clinical myotonia is a burst of
autonomous muscle action potentials that lasts a few seconds
after the cessation of motor neuron activity and delays relaxation.
Given the role played by ClC-1 channels in muscle ﬁbers, the
reduced chloride conductance resulting from ClC-1 mutations
will predispose the sarcolemma to spontaneous action potential
runs or abnormal after-discharges that hamper muscle relax-
ation after contraction, causing myotonia (Lossin and George,
2008).
So far more than 130 mutations in CLCN1 have been iden-
tiﬁed (Lossin and George, 2008; Matthews et al., 2010) over the
entire length of the channel, and the analysis of a number of
ClC-1 naturally occurring mutations in heterologous expression
systems has contributed to the understanding of the molecu-
lar structure and function of the channel and of the disease
pathogenesis. The CLCN1 mutations include small deletions,
insertions, frame-shifts, stop codons, missense and splice-site
mutations (Esteban et al., 1998; Sangiuolo et al., 1998; Brugnoni
et al., 1999, 2013; de Diego et al., 1999; Pusch, 2002; Wu et al.,
2002; Fialho et al., 2007; Lossin and George, 2008; Modoni
et al., 2011; Mazón et al., 2012). Recently, it was demonstrated
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that also CLCN1 exon deletions or duplications in patients with
a single identiﬁed recessive mutation, can cause recessive MC
(Raja Rayan et al., 2012). The majority of MC mutations are
predicted to reduce channel expression by defective traﬃcking
or to cause various alterations of channel function including
shifts of voltage dependence, reduced single channel conduc-
tance, altered ion selectivity (Figure 1B, Table 1; Tsujino et al.,
2011; Ulzi et al., 2012; Weinberger et al., 2012; Desaphy et al.,
2013). A novel mechanism has been proposed for the G200R and
Y261C mutations, which abolished the potentiation of NAD+-
induced ClC-1 channel inhibition by low pHi (Bennetts et al.,
2012).
Some mutations exhibit both a dominant and recessive
inheritance pattern, that complicates our understanding of
the genotype–phenotype correlation and mode of inheritance.
Remarkably, defects in the fast and slow gating modes of the
channel have been proposed to explain the molecular mech-
anisms for dominant and recessive MC forms (Accardi and
Pusch, 2000; Simpson et al., 2004; Weinberger et al., 2012).
Furthermore, structure-function relationships in the ClC-1 chan-
nel provided relevant information to the understanding of the
molecular pathogenesis of MC (Skálová et al., 2013). As a gen-
eral rule, dominant mutations located on one subunit of the
dimer may disrupt the slow gate, thereby exerting a dominant-
negative eﬀect on the unaﬀected associated wild-type subunit.
As the slow gate involves subunits interaction, and helices at
the dimer interface primarily contribute to cooperative gating
(Duﬃeld et al., 2003), this mechanistic hypothesis easily ﬁts to
dominant mutations residing on the boundary region between
two monomers (Fialho et al., 2007). The homology model
of hClC-1 based on the crystallographic structure of CmCLC
allowed to identify residues constituting the dimer interface and
the ion conducting pore, and indeed to validate experimen-
tal data and mechanistic hypotheses (Feng et al., 2010; Skálová
et al., 2013). Indeed, most dominant MC mutations proven to
cause a dominant-negative eﬀect when co-expressed with WT
subunits eﬀectively reside at the boundary region between two
monomers or in its proximity. Conversely, mutations occur-
ring in the channel pore show no dominant-negative eﬀect and
can cause the disease by directly aﬀecting the channel activ-
ity or the local structure of one subunit, or induce misfold-
ing of the mutant subunit (Skálová et al., 2013). On the other
hand, recessive Becker mutations present in both alleles may
limit expression or aﬀect the fast gate of individual subunits,
thereby causing diﬀerent degrees of haploinsuﬃciency. Variation
in symptoms amongst MC patients cannot be fully explained
by the diﬀerent eﬀect of ClC-1 mutations, since relatives car-
rying identical ClC-1 mutations can exhibit markedly diﬀerent
phenotypes (Colding-Jørgensen, 2005). In addition, a number of
ClC-1 mutations found in myotonic carriers show little or no
evidence of defective channel function in heterologous expres-
sion systems (Pusch, 2002; Simpson et al., 2004; Desaphy et al.,
2013; Lucchiari et al., 2013). One possibility is that these vari-
ants might actually modify the phenotype of a co-existing MC
mutation without being frankly pathogenic. Alternatively, these
mutations might impair channel modulation by signaling path-
ways or accessory proteins in the muscle context. In addition,
diﬀerence in allelic expression of CLCN1 may inﬂuence the clin-
ical phenotype (Duno et al., 2004). Last but not least, other
genes may be involved in the phenotype variability, acting as
TABLE 1 | Diseases associated to dysfunction of CLCN1 gene.
Disease Biophysical defect Protein defect Protein domain Reference
Myotonia congenita Similar to WT F167L C Ulzi et al. (2012)
Reduced chloride current due to positive shift of
voltage-dependence of activation; no dominant-negative effect
on WT
G190S D Desaphy et al. (2013)
Reduced chloride current due to positive shift of
voltage-dependence of slow gating; dominant-negative effect
on WT
I290M H-I loop Pusch (2002)
Reduced chloride current due to inverted voltage dependence D136G C Stölting et al. (2014b)
Reduced chloride currents due to reduced single channel
conductance, inverted voltage dependence and reduced open
probabilities of fast and slow gating
C277Y H Weinberger et al. (2012)
Altered halide selectivity and outward rectification at positive
potentials
G230E H Stölting et al. (2014b)
Reduced expression and reduced chloride current due to
sarcoplasmic reticulum retention and enhanced proteasomal
and endosomal degradation
A531V O Papponen et al. (2008),
Desaphy et al. (2013)
Abolished potentiation of NAD+-induced ClC-1 channel
inhibition by low pHi
G200R D Bennetts et al. (2012)
Epilepsy not determined R976X C-terminus Chen et al. (2013)
Myotonic distrophy type I and II Reduced chloride conductance Aberrant splicing Charlet-B et al. (2002),
Mankodi et al. (2002)
Huntington disease Reduced ClC-1 chloride currents Aberrant splicing Waters et al. (2013)
For myotonia congenita, only one representative mutation is listed for each type of biophysical alteration. For an exhaustive review of ClC-1 mutations causing myotonia
congenita, see Pusch (2002).
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disease modiﬁers, although such factors have not been identi-
ﬁed so far (Colding-Jørgensen, 2005). Myotonic symptoms are
known to worsen during pregnancy and with use of diuret-
ics (Bretag et al., 1980; Colding-Jørgensen, 2005; Basu et al.,
2009), both conditions being associated with increased risk of
hypomagnesemia and hypocalcemia (Raman et al., 1991; Skov
et al., 2013). Indeed, the elevation of [Mg2+]o or [Ca2+]o, within
their physiological ranges, dampened 9-AC-induced myotonia
in isolated rat and human muscle ﬁbers (Skov et al., 2013,
2015).
Myotonic Dystrophy
Conversely to MC, myotonic dystrophy is an autosomal domi-
nant multisystemic disease due to expansion of nucleotide repeats
in the DMPK (DM1 or Steinert disease) or ZNF9 (DM2 or proxi-
mal myotonic myopathy or PROMM) genes (Meola, 2013; Meola
and Cardani, 2014). It is the commonest form of muscular dys-
trophy in adults. In both forms, the nucleotide expansion is
transcribed in RNAs that accumulate in the cell nucleus and con-
stitute the so-called foci, which aﬀects the transcription and splic-
ing of various genes. In particular, DMPK- and ZNF9-induced
alteration of CLCN1 transcription have been demonstrated in
several mouse models of DM1 and DM2, and is likely respon-
sible for the observed myotonia (Charlet-B et al., 2002; Mankodi
et al., 2002; Chen et al., 2007; Lueck et al., 2007; Wheeler et al.,
2007; Hao et al., 2008).
In addition, ClC-1 mutations have been found in diagnosed
DM2 patients, which worsen the disease. For instance, the ClC-
1 mutation R894X was shown to enhance myotonia and pain in
DM2 patients (Ursu et al., 2012). In another DM2 patient, the
F167L ClC-1 mutation might explain the unusual early onset
of the disease (Cardani et al., 2012). Thus, it has been hypoth-
esized that DM2 patients with co-segregating CLCN1 mutation
have an increased likelihood to be referred for molecular diag-
nostic testing owing to the exacerbation of the clinical phenotype
(Suominen et al., 2008).
The gCl is also an index of the dystrophic condition of
dystrophin-deﬁcient muscles in the mdx mouse, a model of
Duchenne muscular dystrophy (De Luca et al., 1995). Indeed,
the diaphragm and extensor digitorum longus (EDL) muscles
from mdx mice show a decrease of gCl and an increase of gK.
These changes were very dramatic in diaphragm ﬁbers suggesting
that the impairment of gCl in the degenerating diaphragm could
account for some of the symptoms of the human disease (De Luca
et al., 1997b).
Epilepsy and other Neurological Disorders
Epileptic phenotypes resulting from defects in a number of ion
channel types have been recently classiﬁed as “channelepsies”
(D’Adamo et al., 2013). Evidence for a role of ClC-1 channels
in the pathogenesis of “Cl− -channelepilepsy” is derived from
large-scale exome analysis of ion channel variants and expres-
sion studies (Chen et al., 2013). Indeed, the CLCN1 gene has been
recently proposed as a candidate gene for epilepsy. The anal-
ysis of a cohort of patients suﬀering from idiopathic epilepsy
showed that the occurrence of single nucleotide polymorphisms
in CLCN1 was threefold higher in aﬀected patients compared
to controls. Moreover, a novel ClC-1 premature stop codon
(R976X), resulting in truncation of the distal C-terminus of the
protein, was identiﬁed by exomic sequencing in one patient
with generalized pharmacoresistant epilepsy and mild myotonic
features (Chen et al., 2013). The same study also showed unex-
pected ClC-1 mRNA transcripts and ClC-1 protein bands in
several human brain areas, including hippocampus, cerebellar
Purkinje cell layer, brainstem nuclei, frontal neocortex and tha-
lamic nuclei.
This novel localization of ClC-1 might open new perspectives
regarding the role of CLC channels in the central nervous sys-
tem. First, if ClC-1 is expressed in human brain, then mutations
that reduce chloride conductance could contribute to enhanced
network excitability and increased susceptibility to seizures or
other neurologic phenotypes. A second and intriguing observa-
tion is the presence of ClC-1 in subcortical structures, such as
the basal ganglia, subthalamus, and cerebellar Purkinje cell layer,
which raises the possibility that dysfunction of brain ClC-1might
contribute, in some individuals carrying ClC-1mutations, to the
dystonia phenotype which has previously been regarded as being
exclusively of muscular origin.
However, patients with MC and related animal models do
not experience central neurological symptoms, and to date only
one single case of ClC-1 mutation associated to seizures has
been reported. An hypothesis to explain the low occurrence of
ClC-1-associated epilepsy phenotype considers a compensatory
mechanism possibly involving ClC-2, given the extensive over-
lapping in the regional brain expression of both channels, and
the possible formation of heteromeric channels (Chen et al., 2013;
Stölting et al., 2014a).
The association between hereditary myotonic disorders and
brain diseases has been rarely reported in the literature. The
ﬁrst case of association between familial Thomsen myotonia and
epilepsy has been presented very recently, with the description
of one individual belonging to a two-generation family suf-
fering from ClC-1-linked myotonia, who experienced epileptic
seizures due to limbic encephalitis with antibodies against gluta-
mate decarboxylase (Licchetta et al., 2014). Another recent paper
have reported in a boy the co-existence of a ClC-1mutation caus-
ing recessive MC and of a PMP22 mutation causing dominant
Charcot-Marie-Tooth disease type 1A (Ardissone et al., 2013).
These few “double trouble” cases do not allow to deﬁne whether
the concomitant genetic condition may inﬂuence the severity and
progression of the diseases.
A reduction of ClC-1 channel activity has recently been
described in skeletal muscles of a mouse model of Huntington
disease (HD; Waters et al., 2013). As in myotonic dystrophy,
HD is due to the expansion of a trinucleotide repeat in the HD
gene, and improper clcn1mRNA splicing was shown to compro-
mise ClC-1 channel expression and function. The muscle ﬁbers
of HDmouse were hyper-excitable, with a reduction of threshold
to trigger action potentials, an increased number of ﬁred action
potentials, and the occurrence of spontaneous action potentials,
eventually causing involuntary and prolonged contractions. It
was thus proposed that ClC-1 impairment likely contribute to the
chorea, stiﬀness, and dystonia that characterize HD (Waters et al.,
2013).
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Pharmacology of ClC-1
Much of the information regarding ClC-1 channel pharmacology
has been obtained by studying skeletal muscle chloride conduc-
tance and heterologously expressed ClC-1 channels, leading to
the identiﬁcation of a series of poorly selective blockers and a few
activators (Table 2).
The interest in ClC-1 pharmacology stems primarily from the
lack of a speciﬁc pharmacological treatment for MC patients.
Today, mexiletine, a sodium channel blocker, represents the
ﬁrst line therapy for the myotonic syndromes, irrespective of
the culprit gene. This drug can be eﬀective in reducing stiﬀ-
ness and transient weakness in MC and myotonic dystrophy,
but its use is limited by country availability, side eﬀects and
suboptimal or negative response in some patients (Logigian
et al., 2010; Statland et al., 2012; Lo Monaco et al., 2015).
The ideal drug to treat ClC-1 channelopathy should be one
able to increase chloride currents. However, this goal is far
from being achieved. Two carbonic anhydrase inhibitors, aceta-
zolamide and diclorfenamide, have been used empirically for
their beneﬁcial action on a variety of neurological disorders
including myotonia with variable results (Griggs et al., 1978;
D’Adamo et al., 1999, 2012, 2014, 2015; Imbrici et al., 2008;
Matthews et al., 2010; Markhorst et al., 2014). One possible
mechanism accounting for membrane electrical stabilization by
acetazolamide consists in the opening of calcium-activated potas-
sium channels (Tricarico et al., 2000). More recently, it was
proposed that this drug is also able to shift ClC-1 open prob-
ability toward more negative voltage, probably through change
in pHi, resulting in an increased chloride current and conse-
quently accounting for an antimyotonic eﬀect (Eguchi et al.,
2006; Desaphy et al., 2013). It is, however, possible that the sig-
niﬁcant percentage of non responders stems from a reduced
sensitivity of some mutant channels to the drug (Desaphy et al.,
2013).
In the past, two electrode voltage clamp recordings
from muscle ﬁbers revealed that the R(+)-isomer of
2-(p-chlorophenoxy) propionic acid (CPP) was able to increase
the skeletal muscle chloride conductance at concentrations as
low as 1–5 μM, making it a promising compound in therapy
(Conte-Camerino et al., 1988; De Luca et al., 1992). However,
the opener activity of R-CPP was not observed when applied
to heterologously expressed ClC-1 channels (Aromataris et al.,
1999; Pusch et al., 2000), suggesting an indirect action through
a muscle-speciﬁc component in the native system. Another
attempt to enhance chloride currents has been to indirectly
increase ClC-1 channel expression or function by stimulat-
ing intracellular biochemical pathways. For instance, muscle
chloride conductance increases in vivo and in vitro after appli-
cation of IGF-1 or taurine (De Luca et al., 1996, 1998). PKC
inhibitors, such as staurosporine or chelerythrine, has been
shown to modulate ClC-1 channel (Rosenbohm et al., 1999) and
increase gCl (De Luca et al., 1994a; Pierno et al., 2003), as above
described. Some of them already used in therapy to treat cancer
(i.e., enzastaurin) might be considered for ameliorating ClC-1
channel loss of function. Only recently, lubiprostone, a bicyclic
fatty acid derivative, approved for the treatment of idiopathic
chronic constipation, has been shown to selectively activate
ClC-2 channels without activation of prostaglandin receptors
(Lacy and Levy, 2007). Further studies would be necessary to
verify whether such compound may serve as lead compound for
developing future ClC-1 openers.
Although they lack a direct therapeutic interest, compounds
able to block gCl have proved useful pharmacological tools to
develop animal models of myotonia or to investigate hClC-1
structure-function relationship. For instance, through the reduc-
tion of gCl, 9-AC has been largely used to reproduce myotonia in
isolated muscles or in vivo (Bryant and Morales-Aguilera, 1971;
Skov et al., 2013; Desaphy et al., 2014). Also, cloﬁbrate induces a
myotonic-like state in rodents blocking gCl in a dose-dependent
TABLE 2 | Drugs acting on skeletal muscle gCl and ClC-1.
Drugs Effect on skeletal muscle Mechanism of action Reference
Acetazolamide Improves myotonic symptoms in
affected patients
Increases ClC-1 open probability
likely via a pHi-dependent effect
Eguchi et al. (2006), Matthews
et al. (2010)
Insulin-like growth factor-1 Increases sarcolemma gCl Increases ClC-1 dephosphorylation De Luca et al. (1998)
Taurine Increases sarcolemma gCl Not determined De Luca et al. (1998)
Statins Reduce sarcolemma gCl Increase PKC-dependent ClC-1 phosphorylation Pierno et al. (2006, 2009)
R(+)-CPP Increases sarcolemma gCl Not determined, since it blocks heterologously
expressed ClC-1
De Luca et al. (1992), Pusch
et al. (2000)
9-AC Reduces sarcolemma gCl and
induces myotonic symptoms
Blocks heterologously espressed ClC-1; binds to the
pore from intracellular side
Estévez et al. (2003), Desaphy
et al. (2014)
Fenofibrate, clofibrate and their
metabolites (CPP and CPA)
Reduce sarcolemma gCl and induce
myotonic symptoms
Block heterologously espressed ClC-1; CPP and CPA
bind to the pore from intracellular side
Liantonio et al. (2002), Estévez
et al. (2003), Pierno et al.
(2006, 2009)
Niflumic acid Reduces sarcolemma gCl Blocks heterologously espressed ClC-1; binds to the
pore from intracellular side and increases
PKC-dependent phosphorylation
Liantonio et al. (2007)
9-AC, 9-anthracen carboxylic acid; CPP, 2-(p-chlorophenoxy) propionic acid; CPA, p-chlorophenoxyacetic acid.
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manner (De Luca et al., 1992). A considerable number of cloﬁbric
acid derivatives have been developed and tested in native skeletal
muscle ﬁbers and in heterologously expressed hClC-1 chan-
nels in order to ﬁnd the structural determinants for a selective
channel block. The most active compound resulted to be the
S(−) isomer of CPP, capable of inhibiting ClC-0 and ClC-1
with higher potency than ClC-2 (Pusch et al., 2000; Liantonio
et al., 2002). This compound induces a voltage-dependent block,
reducing currents at negative voltages, thus indicating a higher
aﬃnity toward the closed state of the channel (Aromataris
et al., 1999; Pusch et al., 2001). The p-chlorophenoxyacetic acid
(CPA), as 9-AC, exerts its blocking activity by binding to an
hydrophobic pocket within the channel pore (Accardi and Pusch,
2003; Estévez et al., 2003). Like cloﬁbrate, fenoﬁbrate directly
blocks heterologous-expressed hClC-1 channels, and determined
a reduction of gCl in rat skeletal muscles after in vivo treatment
(Pierno et al., 2006, 2009).
Also the widely-used cholesterol lowering medications,
statins, have been found to reduce the gCl in rat muscles, which
may contribute to the common side eﬀects of the drugs on
muscles. The eﬀects of statins on the gCl is, however, indirect,
involving the PKC-dependent phosphorylation of ClC-1 chan-
nels or a reduction of ClC-1 expression (Pierno et al., 2006,
2009).
Interestingly, niﬂumic acid, a non steroidal anti-inﬂammatory
drug, has been found to decrease muscle gCl by blocking ClC-
1 channels both through direct binding and through Ca2+-
dependent phosphorylation by PKC (Liantonio et al., 2007).
Challenges
A wealth of information about ClC-1 channels have been
acquired during the 25 years since the cloning of the ﬁrst
member of the CLC family. However, several questions still
await an exhaustive answer and represent major challenges to
next research. The molecular identity and mechanism of the
slow gating is still debated and the functions of the two CBS
domains is still under investigation. Little is known about ClC-
1 modulation by intracellular and extracellular factors and,
despite the fact that the role of gCl in skeletal muscle plas-
ticity has been assessed, the underlying molecular mechanisms
are not completely understood. Future investigation will be
committed to understand the possible role of ClC-1 in the
brain and its involvement in the etiopathogenesis of epilepsy,
as well as to face the still unclear aspects of MC, such as
the lack of a precise genetic diagnosis for several patients,
the exact molecular mechanisms for dominant and recessive
inheritance, the mechanisms underlying myotonic symptoms
in patients carrying apparently silent mutations. One major
challenge regards the possibility to guarantee an appropriate
and personalized therapy to MC patients through the iden-
tiﬁcation of speciﬁc pharmacological strategies able to coun-
teract the reduction in chloride conductance that causes MC
(Trivedi et al., 2014). It is expected that the experimental
data already available on ClC-1 blockers, through molecu-
lar dynamics simulations and functional studies, may oﬀer
a solid pharmacophore model for developing selective ClC-1
openers.
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